Search for
Sort by 
Page
Showing 1 - 25 of 534 documents.
Medscape Medical News
Nov 5, 2009 14:15 EST
Two new papers should help put to rest concerns that low serum cholesterol levels may increase cancer risk.
Lipid/Metabolic
Nov 5, 2009 11:45 EST
The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.
Interventional/Surgery
Nov 4, 2009 15:30 EST
The imaging study was the first to show that stenting a non-flow-limiting stenosis of an SVG may help slow or halt the accelerated atherosclerosis that takes place in these vessels. An accompanying editorial cautions that the study does little more than "infer a trend toward anatomic benefit."
Hypertension
2 COMMENTS - Nov 4, 2009 14:30 EST
More discussion about the J-curve in hypertension is published this week; one expert believes the undue attention being paid to this subject might discourage doctors from treating high blood pressure aggressively.
Imaging
6 COMMENTS - Nov 3, 2009 17:00 EST
UPDATED // An 1126-patient trial shows that SPECT and CAC scoring imaging tests are independent and complementary predictors of short- and long-term cardiac risk, respectively.
heartbriefs
Nov 3, 2009 13:15 EST
The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Heart failure
Nov 3, 2009 10:45 EST
Statins for heart failure? After they failed to show much effect in two large randomized trials? Yes—maybe; at least in patients with ischemic heart failure who start the drugs early enough, suggests a post hoc analysis based on one of the trials.
Imaging
15 COMMENTS - Oct 30, 2009 16:00 EDT
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumes—the more commonly seen end point with MRI.
Lipid/Metabolic
Oct 30, 2009 10:00 EDT
The protective effects of diet modification, exercise, and other lifestyle changes against new-onset diabetes showcased in the three-year Diabetes Prevention Program continued out to 10 years in a follow-up analysis.
heartbriefs
2 COMMENTS - Oct 29, 2009 15:30 EDT
Two studies presented this week have shown positive effects on weight loss using a combination of agents.
Medscape Medical News
Oct 29, 2009 12:00 EDT
A new analysis from the Northern Manhattan Study finds that high-sensitivity C-reactive protein was modestly associated with mortality and MI but not ischemic stroke in this multiethnic population, suggesting the predictive value may depend on other factors.
Acute Coronary Syndromes
Oct 29, 2009 10:30 EDT
Two well-known observational registries highlight such changes in women and men over a decade or more: Do women younger than 55 still have an advantage over men in the same age group?
Lipid/Metabolic
Oct 28, 2009 16:30 EDT
Individuals with schizophrenia and diabetes—as opposed to diabetes only—have a greater risk of CAD but a smaller likelihood of receiving CABG or PCI, a large cohort study suggests.
Prevention
1 COMMENT - Oct 27, 2009 16:15 EDT
Among overweight patients, including those with preexisting echocardiographic valvulopathy, the average weight loss was approximately 5 kg with lorcaserin. Importantly, there were no concerns raised about new or worsening cardiac valve problems with the 5HT2C-receptor agonist.
Lipid/Metabolic
1 COMMENT - Oct 27, 2009 10:00 EDT
While post hoc analyses of ACCORD data suggest there are subgroups of diabetic patients who may not benefit from an aggressive glucose-lowering approach, similar analyses with ADVANCE data did not identify subgroup differences.
Prevention
2 COMMENTS - Oct 26, 2009 16:45 EDT
Results showing that people eat less when they know how many calories are in that Big Mac are mixed, but experts say that menu labeling provides only upside, with no public-health cost, and that over time results will show the information to have a positive effect on obesity rates in the US.
heartbriefs
Oct 26, 2009 16:00 EDT
The distribution of body fat, as well as the amount, is important when it comes to the risk of venous thromboembolism, Danish researchers have discovered.
Lipid/Metabolic
1 COMMENT - Oct 26, 2009 10:00 EDT
Intensive lifestyle intervention in the management of diabetes produces sustained weight loss and improvements in fitness, as well as improvements in glycemic control, systolic blood pressure, and HDL-cholesterol levels.
Lipid/Metabolic
9 COMMENTS - Oct 23, 2009 17:00 EDT
Pericardial fat, which is found around the heart, predicts future CHD events and may even be a better predictor of these than conventional obesity measures, such as BMI and waist circumference, a new study of MESA participants shows.
Lipid/Metabolic
Oct 23, 2009 13:30 EDT
The low event rate in the RECORD trial of rosiglitazone has led some to question the validity of the results.
Lipid/Metabolic
Oct 22, 2009 18:30 EDT
A drug originally developed to treat diabetes may have promise as an obesity therapy, a new study shows. Those taking liraglutide, a GLP-1 analog, lost more weight than those on an established obesity medication, orlistat.
Prevention
1 COMMENT - Oct 22, 2009 14:45 EDT
Although the case for intensive glucose lowering in diabetic patients to prevent CVD is not straightforward, glucose control is still important for other reasons, and blood pressure and lipid control should not be neglected, according to debaters at a diabetes meeting.
Prevention
Oct 21, 2009 10:00 EDT
Researchers using different international databases report that the Framingham and UKPDS risk equations overestimate the probability of CV events in diabetic patients.
heartbriefs
4 COMMENTS - Oct 20, 2009 16:00 EDT
The researchers suggest further study is still needed, as it is unclear whether higher doses of omega-3 fatty acids or setraline, longer treatment, or a different ratio of EPA to DHA would produce favorable results.
Lipid/Metabolic
5 COMMENTS - Oct 20, 2009 12:45 EDT
After 10 years of clinical use of TZDs, "we are still at the beginning," and randomized controlled trials shed light on their use in appropriate diabetic patients, speakers at a diabetes symposium reported.

Search for
Sort by 
Page
Showing 1 - 25 of 534 documents.
button

Featured programs
Poll
Do the latest postmarketing surveillance data reassure you about the risk of cancer with ezetimibe?
See: Michael O'Riordan. FDA postmarketing surveillance data show no cancer risk with ezetimibe.
Yes
No

Inside: Lipid/Metabolic
Lipid/Metabolic
13 COMMENTS - Jan 27, 2009 15:53 EST
Reducing CV Risk: What Add-On Therapies Do You Use? Click to take the survey and compare answers. The results will help us create future CME programming